Literature DB >> 27483416

Drug Resistance Characteristics and Macrolide-Resistant Mechanisms of Streptococcus pneumoniae in Wenzhou City, China.

Dakang Hu1, Zheng Sun2, Xinhua Luo1, Shuangchun Liu3, Lianhua Yu1, Ying Qu1, Jinhong Yang4, Jian Yu4, Xiangyang Li4, Jin Zhang1.   

Abstract

BACKGROUND Streptococcus pneumoniae (SP) is a Gram-positive, alpha-hemolytic, facultative anaerobic member of the genus Streptococcus. The erythromycin-resistant methylase (erm) gene and macrolide efflux (mef) gene are the 2 main genes that can mediate SP. Transposon (Tn) also plays an important role in the collection and metastasis of the gene. In the present study we investigated the drug resistance characteristics and the macrolide-resistant mechanisms of SP in Wenzhou City, China. MATERIAL AND METHODS Sixty-eight strains of SP were isolated from sputum samples of hospitalized children in the Second Affiliated Hospital of Wenzhou Medical University. These strains were analyzed using antimicrobial susceptibility tests to determine their drug resistance to 10 kinds of antibacterials. Macrolide-resistant phenotypes were identified using K-B method. PCR method was used to analyze the erm B gene, mef A gene, and int Tn gene. RESULTS Drug resistance rates of 68 strains of SP were 98.5%, 100.0%, 63.2%, 52.9%, 94.1%, 89.7%, 0.0%, 0.0%, 16.2%, and 14.7% for clindamycin, erythromycin, penicillin G, cefotaxime, tetracycline, sulfamethoxazole/trimethoprim, levofloxacin, vancomycin, chloramphenicol, and amoxicillin, respectively. Total detection rates of the erm B gene, mef A gene, and int Tn gene were 98.5%, 91.2%, and 100.0%, respectively. CONCLUSIONS SP shows significant multi-drug resistance in Wenzhou City, whereas there is no clinical value of macrolides antibiotics for SP. cMLSB mediated by erm B gene is the most predominant phenotype among macrolide-resistant SP. The int Tn gene may play an important role in horizontal transfer and clonal dissemination of SP drug resistance genes in Wenzhou City.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27483416      PMCID: PMC4973796          DOI: 10.12659/msm.896766

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


Background

Streptococcus pneumoniae (SP) is a Gram-positive, alpha-hemolytic, facultative anaerobic member of the genus Streptococcus [1]. SP was recognized as a major cause of pneumonia in 1881, and is a major causative organism of invasive and non-invasive diseases, such as community-acquired pneumonia, otitis media, meningitis, and hematosepsis, especially in infants and the elderly [2,3]. In developing countries, there are approximately 1 million deaths caused by SP every year in children under the age of 5 years [4]. The genome of SP is a closed, circular DNA structure that contains between 2.0 and 2.1 million base pairs, depending on the strain. It has a core set of 1553 genes, plus 154 genes contributing to virulence, and 176 genes maintaining a noninvasive phenotype. Genetic information can vary by up to 10% among strains [5]. In the 1980s and before, penicillin was the first-line drug for the treatment of SP. Penicillin antibiotics were among the first medications to be effective against many bacterial infections caused by staphylococci and streptococci [6]. In the 1990s, the first-line drug changed to erythromycin. However, with the wide clinical use of macrolides antibiotics, macrolide-resistant Streptococcus pneumoniae (MRSP) became more prevalent. According to the reports by the Asian Network for Surveillance of Resistant Pathogens (ANSORP), the drug resistance rate of SP to β-lactam or macrolides antibiotics in recent years continued at a high level [7,8]. Moreover, the proportion of multi-drug resistant (MDR) SP was nearly 60% [9,10]. These are challenges to the effective treatment and control of SP infection in children. Erythromycin-resistant methylase (erm) gene and macrolide efflux (mef) gene are the 2 main genes that can mediate SP. Transposon (Tn) also plays an important role in the collection and metastasis of the gene. In order to understand the phenotype of SP and its characteristics, and the drug resistance mechanisms of SP in Wenzhou City, we collected 68 strains of SP and tested erm B gene [11], mef A gene [12], and integrase Tn (int Tn) [13] in this study.

Material and Methods

Material

The standard SP strain ATCC49619 was provided by the Chinese National Center for Medical Culture Collections (Beijing, China). Sixty-eight strains of SP were isolated from sputum samples of hospitalized children in the Second Affiliated Hospital of Wenzhou Medical University in 2009, none of which were repetitive strains. All 68 strains were identified to species level with the Gram-Positive Identification Card (GPI) by automatic microbial analyzer VITEK-32 (bioMérieux Co., Marcy-Etoile, France). They were confirmed with specific PCR of SP species reported by du Plessis [14].

Methods

Antimicrobial susceptibility tests

Sixty-eight strains were analyzed using antimicrobial susceptibility tests to determine their resistance to 10 kinds of antibiotics. ATB STREP 5 were bought from bioMérieux (France) and used according to the manufacturer’s protocol. Macrolide-resistant phenotypes were identified using the disc diffusion test (K-B method) and test papers (erythromycin and clindamycin) were bought from OXOID (UK). When 2 papers are both without inhibition zone, phenotype is considered as constitutive resistance to macrolide, lincosamide, and streptogramin B (cMLSB). When erythromycin is without inhibition zone but clindamycin is with defective inhibition zone (D style), the phenotype is defined as induced resistance to macrolide, lincosamide, and streptogramin B (iMLSB). If erythromycin shows drug resistance and clindamycin is sensitive, it is M phenotype.

Extraction of DNA

SP strains stored at −70°C were placed into Columbia blood agar plates at 37°C for 18–24 h with 5% CO2 (Thermo Electron, USA). After passage, whole bacterial colonies in the plate were collected, and then DNA was extracted with hexadecyl trimethyl ammonium bromide (CTAB) method.

Detection of pbp2B gene, erm B gene, mef A gene, and int Tn gene

Polymerase chain reaction (PCR) method was used to analyze the erm B, mef A, and int Tn genes. And primers of pbp2B gene, erm B gene, mef A gene, and int Tn gene were f 5′-CTGACCATTGATTTGGCTTTCCAA-3′, r5′-TTTGCAATAGTTGCTACATACTG-3′; f 5′-GAA AAG GTA CTC AAC CAA ATA-3′, r5′-AGT AAC GGT ACT TAA ATT GTT TAC-3′; f5′-TGGTTCGGTGCTTACTATTGT-3′, r5′-CCCCTATCAACATTCCAGA-3′; f 5′-GCG TGA TTG TAT CTC ACT-3′, r 5′-GAC GCT CCT GTT GCT TCT-3′, respectively. The PCR reaction system (Eppendorf, Germany) consisted of 0.125 μl 5 U/μl rTaq enzyme, 2.5 μl 10×Buffer, 2.0 μl 2 mmol/L dNTP, 1.5 μl 25 mmol/L MgCl2, 0.5 μl 20 μmol/L primer each (Shanghai Shinegene Molecular Biotechnology Co., LTD., China), 14.875 μl ddH2O, and 3.0 μl DNA template. Reaction conditions were 30 cycles with pre-denaturation at 94°C for 5 min, reduction to annealing temperature for 1 min, then heating to 72°C for 1 min and keeping that for 1 min. Finally, the temperature was kept at 72°C for 10 min. The annealing temperatures for each gene are shown in Table 1. Electrophoresis analysis was done on 2.0% agarose with 0.5 μl PCR products and 1.0 μl 6×loading Buffer for 25 min by PAC3000 (BIO-RAD, USA). Voltage and electric current were set at 150V and 75mA, respectively. Pictures were using a gel photograph system WD-9413A (Beijing Liuyi Instrument, China) after electrophoresis.
Table 1

Annealing temperature and products of PCR.

GeneAnnealing temperatureProduct length
pbp2B55°C682 bp
erm B56°C639 bp
mef A52°C348 bp
int Tn50°C1046 bp

Results

Macrolide-resistant phenotypes of the 68 strains of SP against 10 kinds of antibiotics are shown in Table 2, which shows that the 68 SP strains isolated in the clinic showed a high rate of MDR. Vancomycin, levofloxacin, and chloramphenicol were the only antibiotics with sensitivity higher than 70%. Drug resistance genotypes of the 68 SP strains are shown in Table 3. The Int Tn gene was tested in all 68 strains of SP and the total detection rate was 100.0%.
Table 2

Macrolide-resistant phenotypes of 68 SP strains against 10 kinds of antibiotics.

AntibioticsResistant (%)Intermediate (%)Susceptible (%)
Clindamycin98.50.01.5
Erythromycin100.00.00.0
Penicillin G63.232.44.4
Cefotaxime52.932.414.7
Tetracycline94.10.05.9
Sulfamethoxazole/Trimethoprim89.710.30.0
Vancomycin0.00.0100.0
Levofloxacin0.04.495.6
Chloramphenicol16.20.083.8
Amoxicillin14.736.848.5
Table 3

Drug resistance genotypes of 68 SP strains.

PhenotypesCasesPercent (%)Resistant strainsGenotypes
ErythromycinClindamycinerm Bmef Aerm B + mef A
cMLSB6798.5676766161
iMLSB0000000
M11.510010
Table 2 shows the high-resistant rates of SP against several kinds of antibiotics. Vancomycin, levofloxacin, and chloramphenicol were the only antibiotics with sensitivity higher than 70%, but levofloxacin and chloramphenicol are not suitable for use in children. Table 3 shows that phenotype cMLSB is the predominant type for macrolide resistance of SP in Wenzhou City. Table 3 also shows the high rate of genotype erm B+ mef A and low rates of genotype erm B or mef A alone. The high rate of mef A gene and the low rate of M phenotype were because low-level drug resistance mediated by mef A gene was masked by high-level drug resistance mediated by erm B gene.

Discussion

Drug resistance is the reduction in effectiveness of a drug such as an antimicrobial, anthelmintic, or an antineoplastic in curing a disease or condition. When the drug is not intended to kill or inhibit a pathogen, the term is equivalent to dosage failure or drug tolerance [15]. Sometimes a combination of different classes of antibiotics may be used synergistically; that is, they work together to effectively control bacteria that may be resistant to one of the antibiotics alone [16], but then MDR may appear. It has been reported that more than 30% of SP worldwide are MDR [17]. The data from the PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) study also showed that about 40% of SP strains collected from 38 countries in 2003 and 2004 appeared to have the MDR phenotype; among these, the percentage of MDR to erythromycin was as high as 89.2% [18]. Studies in 15 European countries during 2004–2005 reported that 15.8% of strains of SP were MDR, of which 40.8% were in France and 42.9% in Greece [19]. Compared to other parts of the world, MDR is more common in Asia. According to the ANSORP monitoring study, the total rate of drug resistance in Asia was 26.8% in 2000–2001 and 59.3% in 2008–2009. The highest was 83% in China, followed by 75.5% in Vietnam, 63.9% in South Korea, 62.2% in Hong Kong, and 59.7% in Taiwan [20]. From the results of this study, vancomycin, levofloxacin and chloramphenicol were the only antibiotics with sensitivity higher than 70%, but levofloxacin and chloramphenicol are unsuitable for use in children. However, for children infected with SP, the breakpoint of penicillin was often the same as that of oral preparations in China and elsewhere, and not injection preparation. Minimum inhibitory concentrations (MIC) of oral preparations were ≤0.06, 0.12–1, and ≥2 μg/mL for susceptible, intermediate, and resistant, respectively; MICs of injection preparations were ≤2, 4, and ≥8 μg/mL, respectively. The percentage of cerebrospinal fluid infection was less than 1% in infected types of SP strains isolated clinically. The percentage of MIC ≥4 μg/mL was less than 5%, whereas that of MIC ≥8 μg/mL was less than 1% in SP strains isolated in the clinic, which is almost the same as that reported by Kim et al. [7]. This explains the contradiction between the laboratory results and the clinical efficacy. However, for patients infected with SP, penicillin can still be used as a first-line medication in the clinic, but often with injection preparation. Clinically, the dosage of penicillin has a great range of adjustment (3 times), allowing physicians to easily cope with intermediate patients. For 20 years, the incidence of MRSP has increased due to the wide application of macrolides. The results of Table 2 show that macrolides antibiotics have almost no value in clinical control of SP infection. According to degree of resistance of SP to erythromycin, lincomycin, and streptogramin B, resistance phenotype can be divided into M, MLSB, MSB, and ML, of which M and MLSB are the most common. M type means resistance to erythromycin and susceptibility to lincosamide and streptogramin B, which results from the mef A gene alone. MLSB type means resistance to erythromycin, lincosamide, and streptogramin B, which results from the erm B and/or mef A gene. The main mechanisms of drug resistance of SP to macrolides antibiotics includes the change of ribosome target sites, enhancement of active efflux mechanism, and mutations of genes coding ribosomal protein L4, L22, and (or) rRNA 23S [21]. The erm B gene codes methylase of rRNA 23S, which results in MLSB. According the difference in the upper regulation sequence of the methylase gene, MLSB phenotype is divided into cMLSB and iMLSB. MLSB shows high-level resistance to macrolide (MIC ≥64 mg/L). Mef was discovered in 1996, and includes mef A and mef E. The macrolide-resistant phenotype mediated by mef A was M, while mef A can also transfer in SP [22]. M shows low-level resistance to macrolide (MIC: 1–32 mg/L). There are obvious geographical differences in the prevalence of mef genes and erm B gene [23-25]. In this study, the total detection rate of erm B gene was 98.5%, which indicates that cMLSB phenotype of MRSP coded by erm B gene was the main phenotype in Wenzhou City. In addition, the total detection rate of mef A gene was 91.2%, with only 1.5% M phenotype. This is because low-level drug resistance mediated by mef A gene was masked by high-level drug resistance mediated by the erm B gene. The results of this study were significantly different from the reports in the cities of Shanghai and Guangzhou [26,27]. Mutations of rRNA 23S and (or) genes coding ribosomal protein L4, L22, which were reported in the literature [25], were not found in our study. Some studies suggested that the drug resistance gene of SP is located at conjugative Tn and not at plasmid. Tn1545 can bring erm B gene, tetM gene, catpc194 gene and be efficient to transfer drug resistance genes among strains. Int Tn gene is the integrase gene of Tn1545. Studies have shown that the existence of Tn1545 can be judged through detecting int Tn gene [25,28]. The detection rate of 100.0% for int Tn gene shows its important role in horizontal transfer and clonal dissemination of SP drug resistance genes in Wenzhou City.

Conclusions

The total detection rate of int Tn was 100.0% in this study, indicating that Tn bringing drug resistance genes may be extremely widespread among MRSP strains in Wenzhou City. It also can partly confirm the important status of Tn in the development of SP drug resistance from the side.
  26 in total

1.  Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae.

Authors:  Annie Canu; Brigitte Malbruny; Maëlle Coquemont; Todd A Davies; Peter C Appelbaum; Roland Leclercq
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Simple, accurate, serotype-specific PCR assay to differentiate Streptococcus pneumoniae serotypes 6A, 6B, and 6C.

Authors:  Ping Jin; Meng Xiao; Fanrong Kong; Shahin Oftadeh; Fei Zhou; Chunyi Liu; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

3.  Rapid detection of penicillin-resistant Streptococcus pneumoniae in cerebrospinal fluid by a seminested-PCR strategy.

Authors:  M du Plessis; A M Smith; K P Klugman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

4.  Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae.

Authors:  M Del Grosso; F Iannelli; C Messina; M Santagati; N Petrosillo; S Stefani; G Pozzi; A Pantosti
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 5.  Treatment of acute otitis media - challenges in the era of antibiotic resistance.

Authors:  R Dagan
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

6.  Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.

Authors:  D J Hoban; A K Wierzbowski; K Nichol; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

7.  Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance.

Authors:  David J Farrell; Ian Morrissey; Sarah Bakker; Louise Morris; Sylvie Buckridge; David Felmingham
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

Review 8.  The global threat of antimicrobial resistance: science for intervention.

Authors:  I Roca; M Akova; F Baquero; J Carlet; M Cavaleri; S Coenen; J Cohen; D Findlay; I Gyssens; O E Heuer; G Kahlmeter; H Kruse; R Laxminarayan; E Liébana; L López-Cerero; A MacGowan; M Martins; J Rodríguez-Baño; J-M Rolain; C Segovia; B Sigauque; E Tacconelli; E Wellington; J Vila
Journal:  New Microbes New Infect       Date:  2015-04-16

9.  High prevalence of Streptococcus pneumoniae in adenoids and nasopharynx in preschool children with recurrent upper respiratory tract infections in Poland--distribution of serotypes and drug resistance patterns.

Authors:  Artur Niedzielski; Izabela Korona-Glowniak; Anna Malm
Journal:  Med Sci Monit       Date:  2013-01-18

10.  Biological Efficacy of Streptomyces sp. Strain BN1 against the Cereal Head Blight Pathogen Fusarium graminearum.

Authors:  Boknam Jung; Sook-Young Park; Yin-Won Lee; Jungkwan Lee
Journal:  Plant Pathol J       Date:  2013-03       Impact factor: 1.795

View more
  1 in total

1.  Antimicrobial resistance in beta-haemolytic streptococci in India: A four-year study.

Authors:  Nidhi Bhardwaj; Purva Mathur; Bijayini Behera; Kushal Mathur; Arti Kapil; Mahesh C Misra
Journal:  Indian J Med Res       Date:  2018-01       Impact factor: 2.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.